FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia.
CONCLUSION: At variance with induction results for AML (Peterlin et al., 2019) endogenous sFLc do not appear to be a prognostic marker at the time of or after allo-HSCT. Even though the results are negatives, this is, to the best of our knowledge, the only prospective series specifically addressing the question of sFLc impact after allo-HSCT in acute leukemias.
PMID: 31035172 [PubMed - as supplied by publisher]
Source: Cytokine - Category: Molecular Biology Authors: Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Mahé B, Dubruille V, Godon C, Robillard N, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Bonnet A, Le Gouill S, Moreau P, Béné MC, Tags: Cytokine Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia | Chronic Leukemia | Leukemia | Molecular Biology | Stem Cell Therapy | Stem Cells | Study | Transplants